LobbyingPardes Biosciences lobbying by quarter
Pardes Biosciences's latest lobbying report covers Q2 2023, at $120K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medical/Disease Research/Clinical Labs.
Pardes Biosciences
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $120K | 1 |
| Q1 2023 | $120K | 1 |
| Q2 2023 | $120K | 1 |
| Q3 2023 | $0 | 0 |
| Q4 2023 | $0 | 0 |
| Q1 2024 | $0 | 0 |
| Q2 2024 | $0 | 0 |
| Q3 2024 | $0 | 0 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$90K · 3 reports
- Medical research and clinical labs$90K · 3 reports
- Medicare and Medicaid$90K · 3 reports
- Pharmacy$90K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Centers For Medicare and Medicaid Services (CMS)3 reports
- Food & Drug Administration (FDA)3 reports
- Health & Human Services, Dept of (HHS)3 reports
- HOUSE OF REPRESENTATIVES3 reports
- Natl Institutes of Health (NIH)3 reports
- Office of Science & Technology Policy (OSTP)3 reports
- SENATE3 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-housePardes Biosciences | $360K | 3 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| JOHN MARTIN | Principal Associate Commissioner, FDA Legislative Affairs, Sen. Tom Cotton | Q2 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 23/04/12for Q2 2023 | In-house | $120K |
| 23/04/12for Q1 2023 | In-house | $120K |
| 23/01/17for Q4 2022 | In-house | $120K |